Loading organizations...
§ Private Profile · Belfast, Northern Ireland
Re-Vana Therapeutics is a technology company.
Re-Vana Therapeutics develops sustained-release ocular biologics, reducing frequent topical drug administration. It utilizes proprietary photo-crosslinked technology to engineer implants, enabling room-temperature manufacturing, stable internal pH, and controlled drug stability. This facilitates customized, extended delivery of biologics, peptides, and small molecules directly to the eye.
Michael O'Rourke, with over three decades in drug delivery, particularly ophthalmology, founded Re-Vana Therapeutics. His extensive background in delivery strategy development provided the foundational insight. It addresses critical challenges for prolonged, effective ocular drug delivery.
Re-Vana's products target patients requiring consistent, long-term ocular treatment, improving frequent conventional applications. Its advanced platforms enable efficient management of complex eye conditions. Development expands application to diverse agents, enhancing patient compliance and clinical outcomes.
Re-Vana Therapeutics has raised $15.0M across 2 funding rounds.
Re-Vana Therapeutics has raised $15.0M in total across 2 funding rounds.
Re-Vana Therapeutics has raised $15.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $12M Series A | Robert Avery | ExSight Capital Management, ExSight Ventures, Infocus Capital Partners, Qubis, Techstart Ventures | Announced |
| Jun 1, 2020 | $3M Seed | Firas Rahhal | ExSight Capital Management, Clarendon Fund Managers, RON Weiss, Qubis, Techstart Ventures, Garrett Hamontree | Announced |
Re-Vana Therapeutics is a venture-backed biotechnology company specializing in innovative sustained-release ocular biologics designed to treat serious retinal diseases. Their proprietary photo-crosslinked, biodegradable drug delivery platforms—such as EyeLief®, EyeLief SD™, and OcuLief®—enable controlled, long-term release of a broad range of therapeutic molecules including biologics, peptides, and small molecules. This technology aims to significantly reduce the treatment burden on patients by extending drug delivery duration to six months or more, improving outcomes for those with sight-threatening conditions like wet age-related macular degeneration (AMD) and glaucoma[1][2].
The company serves pharmaceutical partners and healthcare providers by developing customizable ocular drug delivery systems that address the unmet need for less frequent intravitreal injections. Re-Vana has demonstrated growth momentum through strategic collaborations with global pharmaceutical companies, including Boehringer Ingelheim, and ongoing preclinical development efforts to expand its therapeutic pipeline[2][3].
Founded in 2016 as a spinout from Queen’s University Belfast, Re-Vana Therapeutics emerged from academic research focused on long-acting ocular drug delivery technologies. The founding team leveraged expertise in biotechnology and ophthalmology to develop photo-crosslinked biodegradable hydrogels that can be fabricated in situ within the eye, enabling sustained therapeutic release. Early traction included successful completion of innovation programs like ICURe and securing venture backing to advance preclinical and formulation studies. The company has since evolved its focus to become a leader in sustained-release biologics for retinal diseases, building partnerships to accelerate commercialization[3][4].
Re-Vana is positioned at the intersection of biotechnology and drug delivery innovation, riding the trend toward sustained-release therapeutics that improve patient compliance and outcomes in chronic diseases. The timing is critical as retinal diseases like AMD and diabetic retinopathy represent growing global health burdens with significant unmet treatment needs. Market forces such as increasing demand for biologics, advances in biomaterials, and the push for minimally invasive therapies favor Re-Vana’s approach. By pioneering in situ photo-crosslinked ocular implants, Re-Vana influences the broader ecosystem by setting new standards for sustained biologic delivery and enabling pharmaceutical partners to extend the lifecycle and efficacy of their drugs[1][2][3].
Looking ahead, Re-Vana Therapeutics is expected to advance its sustained-release platforms through clinical trials and expand its product pipeline to cover a wider range of vision-threatening diseases. Trends such as personalized medicine, biologics innovation, and patient-centric care models will shape their journey. Their influence may grow as they establish more strategic collaborations and potentially commercialize first-in-class ocular implants that transform treatment paradigms. Re-Vana’s vision of reducing treatment burden while enhancing therapeutic efficacy positions it as a key innovator in ocular drug delivery with significant potential to impact patient outcomes globally[3][2].
Re-Vana Therapeutics has raised $15.0M in total across 2 funding rounds.
Re-Vana Therapeutics's investors include Robert Avery, ExSight Capital Management, ExSight Ventures, InFocus Capital Partners, QUBIS, Techstart Ventures, Firas Rahhal, Clarendon Fund Managers, Ron Weiss, Garrett Hamontree.